These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Characteristics of gram-negative urinary tract infections caused by extended spectrum beta lactamases: pivmecillinam as a treatment option within South Dublin, Ireland. O'Kelly F, Kavanagh S, Manecksha R, Thornhill J, Fennell JP. BMC Infect Dis; 2016 Nov 03; 16(1):620. PubMed ID: 27806687 [Abstract] [Full Text] [Related]
3. Effective Oral Combination Treatment for Extended-Spectrum Beta-Lactamase-Producing Escherichia coli. Al-Tamimi M, Abu-Raideh J, Albalawi H, Shalabi M, Saleh S. Microb Drug Resist; 2019 Oct 03; 25(8):1132-1141. PubMed ID: 31107146 [Abstract] [Full Text] [Related]
4. Favourable effect of clavulanic acid on the minimum inhibitory concentrations of cefixime and ceftibuten in ESBL-producing Escherichia coli and Klebsiella pneumoniae. Martinez-Guerra BA, Xancal-Salvador LF, Esteban-Kenel V, Tello-Mercado AC, Bobadilla-Del-Valle M, Sifuentes-Osornio J, Ponce-de-Leon A, Gonzalez-Lara MF. J Glob Antimicrob Resist; 2024 Sep 03; 38():212-215. PubMed ID: 38945364 [Abstract] [Full Text] [Related]
5. Antimicrobial susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in health care-associated urinary tract infection: focus on susceptibility to fosfomycin. Cho YH, Jung SI, Chung HS, Yu HS, Hwang EC, Kim SO, Kang TW, Kwon DD, Park K. Int Urol Nephrol; 2015 Jul 03; 47(7):1059-66. PubMed ID: 26026972 [Abstract] [Full Text] [Related]
6. Aminoglycoside therapy for childhood urinary tract infection due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae. Han SB, Lee SC, Lee SY, Jeong DC, Kang JH. BMC Infect Dis; 2015 Oct 13; 15():414. PubMed ID: 26464143 [Abstract] [Full Text] [Related]
11. Extended-spectrum beta-lactamase-producing Enterobacteriaceae in hospital urinary tract infections: incidence and antibiotic susceptibility profile over 9 years. Toner L, Papa N, Aliyu SH, Dev H, Lawrentschuk N, Al-Hayek S. World J Urol; 2016 Jul 13; 34(7):1031-7. PubMed ID: 26511749 [Abstract] [Full Text] [Related]
13. In Vitro and In Vivo Activity of Amoxicillin-Clavulanate Combined with Ceftibuten or Cefpodoxime Against Extended-Spectrum β-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae. Gupta A, Malik S, Kaminski M, Landman D, Quale JM. Microb Drug Resist; 2022 Apr 13; 28(4):419-424. PubMed ID: 35451880 [Abstract] [Full Text] [Related]
18. Antimicrobial susceptibility and emerging resistance determinants (blaCTX-M, rmtB, fosA3) in clinical isolates from urinary tract infections in the Bolivian Chaco. Bartoloni A, Sennati S, Di Maggio T, Mantella A, Riccobono E, Strohmeyer M, Revollo C, Villagran AL, Pallecchi L, Rossolini GM. Int J Infect Dis; 2016 Feb 13; 43():1-6. PubMed ID: 26686940 [Abstract] [Full Text] [Related]
19. Breaking Antimicrobial Resistance: High-Dose Amoxicillin with Clavulanic Acid for Urinary Tract Infections Due to Extended-Spectrum Beta-Lactamase (ESBL)-Producing Klebsiella pneumoniae. Wilkowski P, Hryniewiecka E, Jasińska K, Pączek L, Ciszek M. Ann Transplant; 2023 May 16; 28():e939258. PubMed ID: 37190675 [Abstract] [Full Text] [Related]